Related Experiment Video
Updated: Apr 15, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Treatment of hypoglycaemic diabetics in a prehospital setting is safe
Nikolaj Preuss Hatting1, Søren Mikkelsen
1Anæstesi- og intensivafdeling, Odense Universitetshospital, Søndre Boulevard 29, 5000 Odense C, Denmark. doktorsmolf@dadlnet.dk.
Introduction:
Patients with diabetes suffering from hypoglycaemia may be treated by a Mobile Emergency Care Unit (MECU) and are often released at the scene following treatment. Some of these patients experience secondary hypoglycaemia and require renewed treatment or admission to hospital. The present study was initiated in order to investigate the extent of secondary hypoglycaemia, to evaluate the appropriateness of the current treatment practice, and to provide practical suggestions for the hand-ing of prehospital hypoglycaemia.
Methods:
All MECU runs are registered in a database by the attending physician who states the patients' identity, treatment, outcome and diagnosis. Over a period of four years (1 May 2006-30 April 2010), all missions related to hypo-glycaemia were reviewed. Each entry was cross-referenced with the patient's hospital files to detect any recurrent hypoglycaemic episodes within 24 hours from initial contact.
Results:
The MECU treated 138 hypoglycaemic cases of whom 50% were released at home following treatment. Four of these patients experienced secondary hypoglycaemia. Two were treated by the MECU and two were admitted through the emergency department without contact to the MECU.
Conclusion:
The number of patients suffering from secondary hypoglycaemia following treatment by the MECU is acceptable and in line with numbers reported by similar organisations.
Funding:
not relevant.
Trial Registration:
not relevant.
More Related Videos
07:35Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique
Published on: January 26, 2024
04:41Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
Published on: July 25, 2025
Related Concept Videos
Hypoglycemia and Glucagon
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Oral Hypoglycemic Agents: Glinides
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...